Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Acerus Pharmaceuticals Corporation (T:ASP)

Business Focus: Pharmaceuticals

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEDAR
Company Contact
Address: 2486 Dunwin Dr
Tel: N/A
IR: See website
Key People
Ian O. Ihnatowycz
Independent Chairman of the Board
Edward Joseph Gudaitis
President, Chief Executive Officer, Director
Robert M. Motz
Chief Financial Officer
Patricia Symmes
Chief Operating Officer
Nathan Bryson
Chief Scientific Officer
Philippe Savard
Vice President, General Counsel, Corporate Secretary
Business Overview
Acerus Pharmaceuticals Corporation, formerly Trimel Pharmaceuticals Corporation, is a Canada-based pharmaceutical company. The Company is engaged in the development, manufacture, marketing and distribution of products with a focus on men's health, including urology, and women's health, including hormone replacement therapy and female sexual dysfunction. The Company markets Estrace in Canada, which is an oral, plant-derived 17-beta estradiol therapy for the relief of symptoms of menopause. The Company offers Natesto, which is the testosterone nasal gel in the United States for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). The Company offers TEFINA, which is a low-dose nasal testosterone gel treatment in development for female sexual dysfunction. The Company focuses on TriVair Deposition/Dispersion System, which is a unit dose dry powder inhaler and nasal dispersion system.
Financial Overview
For the three months ended 31 March 2020, Acerus Pharmaceuticals Corporation revenues decreased 93% to $145K. Net loss increased 5% to $4.7M. Revenues reflect Canada segment decrease of 97% to $40K, United states segment decrease of 89% to $105K. Higher net loss reflects Selling and marketing increase from $409K to $2.1M (expense), Interest on long-term debt and other fin increase of 31% to $846K (expense).
Employees: 11 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $75.49M as of Mar 31, 2020
Annual revenue (TTM): $2.37M as of Mar 31, 2020
EBITDA (TTM): -$17.81M as of Mar 31, 2020
Net annual income (TTM): -$22.15M as of Mar 31, 2020
Free cash flow (TTM): -$19.20M as of Mar 31, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 1,010,456,066 as of Mar 31, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization